SCHEMBL30797146

SCHEMBL30797146

Nc1nnc(Cl)cc1N1C[C@H]2CC[C@@H](C1)N2c1nccc(C2CCN(C(=O)OCc3ccccc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPC3 Q13507 2/20 0.43
▸ TRPC7 Q9HCX4 2/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GRIN2B Q13224 7/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CYP2D6 P10635 3/20 0.39
▸ CYP2C9 P11712 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ SMARCA2 P51531 2/20 0.38
▸ SMARCA4 P51532 2/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ JAK1 P23458 2/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ FAAH O00519 1/20 0.38
▸ PRMT5 O14744 1/20 0.37
▸ ENPP2 Q13822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797069 0.87 SMARCA2 (0.38) SMARCA2SMARCA4
SCHEMBL30796719 0.86 SMARCA2 (0.43) TRPC3TRPC7SMN1; SMN2CYP2C19GRIN2B
SCHEMBL29942646 0.85 SMARCA2 (0.38) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL30797119 0.83 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL30796771 0.83 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL30796727 0.80 SMN1; SMN2 (0.48) TRPC3TRPC7SMN1; SMN2CYP2C19GRIN2B
SCHEMBL30796962 0.79 PRMT5 (0.50) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL23301277 0.79 LNPEP (0.43) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL30796273 0.78 HDAC1 (0.50) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL29221603 0.78 HDAC1 (0.50) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
Send feedback